We're dedicated to providing safe and effective medicines, alongside services and support for healthy outcomes. This involves superior science, creativity, and collaboration with stakeholders at all levels. As a leading pharma company in the U.S., we focus on devastating diseases and complex medical challenges across six specific therapeutic areas: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Janssen is interested in funding programs and initiatives that improve patient access to treatment and services, advance health equity, and strengthen frontline health workforces within the noted therapeutic areas. The grant supports disease awareness efforts, patient empowerment and advocacy, and linkages to care, with a preference for programs focused on health system improvement with measurable outcomes over fundraising activities. Specifically, in the Cardiovascular & Metabolism therapeutic area, they support programs assisting patients and caregivers impacted by disease areas such as Stroke Prevention in Atrial Fibrillation for obese populations, Thromboembolic Disease for both adult and pediatric patients at risk for VTE, and Vascular Protection to prevent amputation. Interest areas include patient and caregiver education, family/caregiver support and wellness, advocacy support, efforts to empower disease management, anti-coagulant therapy assistance, professional and caregiver skill-building for improved patient outcomes, and initiatives addressing healthcare disparities and advocating for access to care for individual patient needs.
ad culpa ad velit elit eiusmod in nisi anim anim fugiat eiusmod elit sunt sint